A randomized phase 2 study of a human antiplatelet-derived growth factor α (PDGFRα) monoclonal antibody (olaratumab, IMC-3G3) with paclitaxel/carboplatin or paclitaxel/carboplatin alone in previously untreated patients with advanced non-small cell lung cancer (NSCLC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 8050-8050 ◽  
Author(s):  
David E. Gerber ◽  
Toby Christopher Campbell ◽  
Paul Swanson ◽  
Ariel Lopez-Chavez ◽  
Lucas Wong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Monoclonal Antibody ◽  
Growth Factor ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Phase 2 Study ◽  
Factor Α ◽  
Randomized Phase 2

scholarly journals ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

Cancer ◽  
2018 ◽  
Vol 124 (24) ◽  
pp. 4667-4675 ◽  
Author(s):  
Daniel Morgensztern ◽  
Manuel Cobo ◽  
Santiago Ponce Aix ◽  
Pieter E. Postmus ◽  
Conrad R. Lewanski ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Phase 2 Study ◽  
Randomized Phase 2
Sign in / Sign up

Export Citation Format

Share Document